Publication:
Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials

Simple item page
dc.contributor.authorMarcellin, Patrick
dc.contributor.authorGane, Edward J.
dc.contributor.authorFlisiak, Robert
dc.contributor.authorTrinh, Huy N.
dc.contributor.authorPetersen, Joerg
dc.contributor.authorGürel, Selim
dc.contributor.authorKaita, Kelly D.
dc.contributor.authorKotzev, Iskren A.
dc.contributor.authorTsai, Naoky
dc.contributor.authorFlaherty, John F.
dc.contributor.authorSchall, Raul E. Aguilar
dc.contributor.authorKitrinos, Kathryn M.
dc.contributor.authorSubramanian, Mani
dc.contributor.authorMcHutchison, John G.
dc.contributor.authorGeorge, Jacob
dc.contributor.authorJanssen, Harry L.
dc.contributor.authorButi, Maria
dc.contributor.buuauthorGÜREL, SELİM
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2024-08-15T12:13:29Z
dc.date.available2024-08-15T12:13:29Z
dc.date.issued2014-01-01
dc.descriptionBu çalışma, 07-11, Kasım 2014 tarihlerinde Boston[Amerika]’da düzenlenen 65. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.identifier.eissn1527-3350
dc.identifier.endpage314A
dc.identifier.issn0270-9139
dc.identifier.startpage313A
dc.identifier.urihttps://hdl.handle.net/11452/44079
dc.identifier.volume60
dc.identifier.wos000344483801163
dc.indexed.wosWOS.SCI
dc.indexed.wosWOS.ISTP
dc.language.isoen
dc.publisherWiley
dc.relation.journalHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectGastroenterology & hepatology
dc.titleLong term treatment with tenofovir disoproxil fumarate for chronic hepatitis b infection is safe and well tolerated and associated with durable virologic response with no detectable resistance: 8 year results from two phase 3 trials
dc.typeMeeting Abstract
dspace.entity.typePublication
relation.isAuthorOfPublicationd7a9ea11-69fc-4122-a365-8fb2123512e6
relation.isAuthorOfPublication.latestForDiscoveryd7a9ea11-69fc-4122-a365-8fb2123512e6

Files

Collections

Yeni Yayınlar